March 5, 2026- Newly published research by Cleveland Clinic and Dyania Health demonstrates how a medically trained large language model system can accurately and efficiently screen electronic medical records (EMRs) to identify patients who are eligible for a rare disease clinical trial.
Published in The Journal of Cardiac Failure, the official journal of the Heart Failure Society of America, the study offers real-world evidence that artificial intelligence (AI)-enabled medical chart review can improve the speed, accuracy and equity of trial enrollment.
The study assessed the performance of an AI system – developed by Dyania Health and deployed at Cleveland Clinic – tasked with pre-screening participants for DepleTTR-CM, a Phase 3 trial for transthyretin amyloid cardiomyopathy (ATTR-CM), a type of heart failure mostly seen in older adults. In one week, the system reviewed 1,476 patients and identified 46 as potential matches.